184 results about "Amyloid like" patented technology

The invention belongs to the field of bioengineering, and discloses construction of anti-micro-nano bubble escherichia coli and application of the anti-micro-nano bubble escherichia coli in efficient carbon sequestration synthesis of succinic acid. Escherichia coli for producing succinic acid is used as a starting strain, amyloid fibrin (Curli) is amplified and constructed to form an overexpression plasmid of a key gene CsgA, and the starting strain is introduced to obtain an overexpression strain. According to the constructed micro-nano bubble resisting escherichia coli, CO2 micro-nano bubbles serve as the only CO2 donor, no carbonate or bicarbonate needs to be supplemented in the anaerobic fermentation process, cells have excellent resistance to the CO2 micro-nano bubbles, growth and metabolism of the cells are not remarkably inhibited, good succinic acid production performance is kept, and the method is suitable for industrial production. The introduction of CsgA greatly improves the actual utilization efficiency of CO2 gas by thalli, is beneficial to reducing the production cost of succinic acid and improving the environmental benefits of succinic acid, and has wide social and economic values.

The invention relates to a deep learning-based early-stage amyloidosis nephropathy identification and diagnosis method, belongs to the technical field of amyloidosis nephropathy identification, and solves the problem that early-stage amyloidosis cannot be accurately identified in the prior art. The method comprises the following steps: acquiring kidney pathological section images of different individuals to construct a training sample set; constructing a link model comprising a first region segmentation model, a second region segmentation model and a third region segmentation model; the first region segmentation model is used for segmenting a cortex region in the pathological image; the second region segmentation model is used for segmenting a glomerular region; the third region segmentation model is used for identifying amyloidosis of a glomerular region; training the link model based on the training sample set to obtain a trained link model; and inputting a to-be-identified kidney pathological section image into the trained link model to identify whether amyloidosis exists or not. And efficient and accurate early-stage amyloidosis identification is realized.

The invention provides a prediction method and device for diagnosing myocardial amyloidosis, and is applied to the technical field of data processing. The method comprises the steps of performing data cleaning processing on a first training sample set to generate a second training sample set; performing missing value supplement processing on the second training sample set to generate a target training sample set; processing a preset myocardial amyloidosis prediction model based on the target training sample set and the verification sample set to generate a target myocardial amyloidosis prediction model; processing the clinical parameter information of the target user to generate target physiological parameter information; processing the living habit information of the target user to generate a dynamic risk adjustment factor; the target physiological parameter information and the dynamic risk adjustment factor are processed based on the target myocardial amyloidosis prediction model, early warning information is generated, and the early warning information is used for representing the relevance between the target user and myocardial amyloidosis, hypertrophic cardiomyopathy and hypertension left ventricular hypertrophy.

The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.

The invention provides application of a biomarker combination for early screening and diagnosis of transthyretin cardiac amyloidosis (ATTR-CA) high-risk groups in preparation of a product for early screening and diagnosis of the ATTR-CA high-risk groups. In general, one or more biomarkers, such as total prealbumin (total PA), transthyretin (TTR) tetramer, misfolded protein, protein misfolding rate, and soluble growth stimulus expression gene 2 protein (sST2). In ATTR-CA high-risk groups and non-high-risk groups, the biomarkers show significant difference, which prompts that the biomarkers are related to ATTR-CA. When a plurality of biomarkers are combined for use, the biomarkers have relatively high sensitivity and specificity in early screening and diagnosis of ATTR-CA high-risk groups, have relatively high diagnosis efficiency, and provide a new thought and strategy for early diagnosis and treatment of ATTR-CA.

The invention relates to the technical field of peanut functional protein structure application, in particular to a peanut protein amyloid fiber and a preparation method thereof. The method specifically comprises the following steps: (1) mixing peanut meal with an organic solvent, degreasing to obtain degreased peanut powder, and preparing the degreased peanut powder into a degreased peanut powder solution; (2) centrifuging the degreased peanut powder solution for the first time, taking a supernatant, adjusting the pH value, standing, centrifuging for the second time, taking a precipitate, dialyzing, and freeze-drying to obtain peanut protein isolate; (3) hydrating the peanut protein isolate, centrifuging for the third time, taking supernatant to obtain a peanut protein isolate solution, adjusting the pH value, centrifuging for the fourth time, taking supernatant, and filtering to obtain a protein solution; and (4) carrying out fibrosis treatment on the protein solution to obtain the peanut protein amyloid fiber. The preparation method provided by the invention can improve the generation amount of the peanut protein amyloid fiber and increase the length of the fiber, and provides a theoretical basis for the application of the peanut protein amyloid fiber in the food industry.

The invention discloses a method for preparing ice cream by using soybean protein amyloid fiber, and belongs to a soybean byproduct utilization technology. The method comprises the following steps: (1) preparing the soybean protein amyloid fiber; (2) compounding ice cream; (3) preparing an ice cream emulsion; and (4) hardening and forming. According to the method, the characteristic that the soybean protein amyloid fiber can better inhibit ice crystallization is applied, the melting rate of ice cream is reduced to 26.38 + / -0.12 from the original 37.17 + / -0.03, and the SAFs content reaches 4.00 + / -0.34%. An experiment for inhibiting ice crystallization by amyloid fibers proves that SAFs prove the ice crystallization activity in the low-calorie ice cream stored at-18 DEG C for 7 days. The APFs are adsorbed on an air-water and fat-water interface, and the APFs have significant influence on the melting rate, appearance and color, particle size distribution, hardness, rheological properties and smell flavor of the ice cream. The research proves that SAFs is a cheap food-grade ice crystal active substance and has great potential in frozen desserts such as ice cream.

Compounds and compositions comprising compounds that modulate histone acyltransferase (HAT). Methods of treating neurodegenerative disorders, conditions associated with amyloid-beta peptide deposit accumulation, Tau protein levels, and / or alpha-synuclein accumulation, and cancer by administering to a subject a compound that modulates HAT.

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

To provide a novel amyloid beta (A beta) binding molecule, especially an amyloid beta antibody or an antigen-binding fragment thereof, and / or use of them.SOLUTION: There is provided an amyloid beta binding antibody including: VH-CDR1 including a specific amino acid sequence, VH-CDR2 including a specific amino acid sequence, VH-CDR3 including a specific amino acid sequence, VL-CDR1 including a specific amino acid sequence, VL-CDR2 including a specific amino acid sequence, and VL-CDR3 including a specific amino acid sequence; or an antigen-binding fragment thereof. In one embodiment, independently of an amyloid beta peptide or a three-dimensional structure states of a seed, an amyloid beta binding antibody or an antigen binding fragment thereof selectively binds to an amyloid beta peptide or seed in a solution, or captures the amyloid beta peptide or seed.SELECTED DRAWING: None

One aspect relates to a method for providing information for predicting a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and / or a positron emission tomography (PET)-positive risk group for amyloid β deposition, based on a European population-East Asian data. According to one aspect, the method makes it possible to accurately predict a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and / or a positron emission tomography (PET)-positive risk group for amyloid β deposition by using only at least 12 single-nucleotide polymorphisms, and the ability to predict the risk groups is further enhanced when up to and at most 80 additional single-nucleotide polymorphisms are used. In addition, the method further includes identifying age, sex, years of education, and APOE genotype as indicators, and thus the ability to predict the risk groups is further enhanced, and the risk groups can be predicted at an early stage with high accuracy.

The invention discloses a nano flocculant as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing a protein amyloid fiber solution; adding a zirconium salt compound, and mixing to obtain a zirconium ion-loaded protein amyloid fiber composite solution; and mixing with a poly dimethyl diallyl ammonium chloride solution. The nano flocculant provided by the invention can be stored for a long time at normal temperature, is simple and convenient to use, is suitable for double improvement of sedimentation efficiency and dephosphorization effect in municipal and industrial sewage treatment processes, and has wide engineering application prospects and environmental friendliness.

The invention discloses a preparation method and application of a compound with emulsifying and antibacterial dual functions, and belongs to the technical field of food active packaging materials. The compound is prepared through a two-step method, a synergistic antibacterial mechanism is formed by means of the hydrophobic binding effect of the amyloid fiber and the cationic electrostatic interaction of the chitosan, and meanwhile excellent emulsion stability and antibacterial activity are achieved through the hydrogen bond-electrostatic interaction of the amyloid fiber and the chitosan. When the compound is applied to preparation of the polysaccharide-based composite film, the mechanical property of the film can be remarkably improved. The raw materials are all natural degradable components, the preparation process is simple, and the obtained composite film can efficiently prolong the shelf life of aquatic products, conforms to the green packaging development trend and has important application value in the field of food active packaging.

Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLPIRA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.

The invention discloses a method for improving the starch digestibility inhibition effect of a spray drying method by using high amylose, and belongs to the technical field of food processing. According to the invention, highland barley glutelin, low-amylose-content corn starch, normal-amylose-content corn starch and high-amylose-content corn starch are selected, and a spray drying technology is used to simulate an embedding structure of protein in a natural grain structure on the surface of starch particles. The method comprises the following steps: dissolving protein in a 0.02% NaOH solution, then adding corn starch with different amylose contents, stirring for 30 minutes, then carrying out spray drying treatment, controlling the addition amount of the protein to be 10% of the total mass of the starch, setting the inlet temperature of a spray dryer to be 170 DEG C, setting the outlet temperature to be 80 DEG C, and controlling the feeding speed of a peristaltic pump to be 35 mL / min; the appearance of the prepared starch sample is similar to the spatial structure in highland barley grains, and the digestibility of the highland barley grains is reduced.

The invention discloses application of a miR-3960 inhibitor, and belongs to the technical field of biological medicines. The invention aims to find and discover miRNA markers related to AD diagnosis and treatment. Researches on AD pathogenesis discover that expression of the miR-3960 is significantly increased in AD patients, and further cell experiments discover that inhibition of the expression of the miR-3960 significantly improves the influence of A beta1-42 on cell viability, apoptosis, ROS and APP proteins, and the miR-3960 has a significant therapeutic effect on AD. A beta1-42 is a core component of amyloid plaque in the brain of an AD patient, and is widely applied to construction of AD cell models and animal models so as to research pathogenesis and drug evaluation of AD. The miR-3960 inhibitor is used for preparing a medicine for treating the Alzheimer's disease, and the nucleotide sequence of the miR-3960 inhibitor is CCCCCGCCUCCGCCGCCGCC.

The invention discloses a mineralized amyloid basal bone repair protein fiber material and a preparation method thereof. The mineralized amyloid basal bone repair protein fiber material is obtained by compressing in a single direction after polyacrylic acid is adsorbed on the surface of a phase transformation protein nano-film, longitudinally stretching and then performing intra-fiber mineralization. According to the preparation method, a phase-transition protein nano-film is converted into crystalline amyloid fiber with high order and a multi-layer structure through mechanical orientation two-step conversion, and interlayer deposition of hydroxyapatite in the amyloid fiber is promoted under the effect of interlayer confinement by controlling mineralization conditions; the process is similar to intra-fiber mineralization of collagen in nature. The mineralized amyloid basal bone repair protein fiber material disclosed by the invention shows good biocompatibility and cell affinity, provides a favorable microenvironment for proliferation, migration and differentiation of cells, and is beneficial to regeneration and repair of bone tissues.

The present invention refers to a vaccine composition comprising amyloid beta 33-40 (Aβ33-40) peptide with an additional cysteine in the N-terminal end (CysAβ33-40) conjugated with the carrier protein keyhole limpet hemocyanin (KLH) using as the crosslinking agent the maleimidobutiric acid N-hydroxysuccinimide ester (SM) and aluminium hydroxide gel as adjuvant for the treatment and / or prevention of cerebral amyloid angiopathy (CAA), the method comprising administering a therapeutically effective amount of said vaccine composition comprising to a patient in need thereof.

Provided herein is a method of detecting an amyloid peptide in a patient sample, including exposing the patient sample to a binding reagent in the presence of an assay binding buffer, thereby immunoprecipitating the amyloid peptide; washing the immunoprecipitated amyloid peptide; eluting the washed, immunoprecipitated amyloid peptide, thereby generating free amyloid peptide; and analyzing the free amyloid peptide with a mass spectrometer.

The application discloses a micro electrochemical sensor for detecting amyloid polypeptide A beta 1‑42 and a preparation method and application thereof. The preparation method comprises the following steps: taking an acupuncture needle as a bare electrode, sequentially modifying tetrachloroauric acid trihydrate-gold nanoparticles, single-wall carbon nanotubes, hemin, amyloid polypeptide A beta 1‑42 template molecules, mixed polydopamine and ion liquid to form an imprinting polymer, and then eluting to obtain the micro electrochemical sensor ANME / / hemin / / SMIP electrode. The micro electrochemical sensor can be used for high-sensitivity detection of amyloid polypeptide A beta 1‑42 , and realizes specific detection of amyloid polypeptide A beta 1‑42 .

Disclosed is a method for measuring an Aβ peptide, comprising: mixing a blood sample comprising an Aβ peptide and an antibody that specifically binds to the Aβ peptide to form a complex of the Aβ peptide and the antibody; releasing the AP peptide from the complex with a basic solution comprising an organic solvent; and measuring the released Aβ peptide by mass spectrometry.

A peptide-based vaccine for use in the treatment or prevention of amyloid-to-thyroid amyloidosis (ATTR) is provided.

This invention provides material compositions and / or methods suitable for the prevention and / or treatment of protein depletion (protein deficiency), comprising material compositions that preserve the natural function of peptides / proteins while limiting and / or preventing the formation and / or aggregation of said peptides / proteins into amyloid protein. It also provides material compositions and formulations for enhancing peptide / protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, and promoting peptide / protein synthesis and purification.

The present invention discloses a method for monitoring the amyloid fibrillization process of lysozyme based on cluster luminescence. The method utilizes the property that lysozyme itself can emit fluorescence in an aggregated state, and the intensity of the fluorescence changes with the change of the aggregation state of lysozyme, thereby achieving the purpose of monitoring the amyloid fibrillization process of lysozyme. The method only needs to perform fluorescence detection on the fluorescence of the protein solution that can form amyloid fiber aggregates, without the introduction of exogenous fluorescent probes. The method is simple and has lower cost. The method can fully present the overall process of amyloid fibrillization and has the advantage of high sensitivity, especially high sensitivity to the early stages of amyloid fibrillization.

To provide a high immunogenicity anti Aβ vaccine while maintaining an excellent safety profile.SOLUTION: A liposome vaccine composition includes a peptide antigen derived from β-amyloid (Aβ) presented on a surface of a liposome. The vaccine composition further includes a peptide including a universal T-cell epitope encapsulated into the liposome. The vaccine composition also may form a part of the liposome, and includes an adjuvant that may be at least partially presented on the surface of the liposome. The vaccine compositions are used for treating or preventing a disease or a condition related to amyloid beta, or symptoms characterized in loss of cognitive memory ability of a subject or a condition related thereto, inducing protective immune response to the symptom, or alleviating the symptoms. The vaccine composition may be provided as a kit. A related method for producing a liposome vaccine composition is also provided.SELECTED DRAWING: None

Provided herein are compositions comprising a nucleic acid encoding an amyloid-beta precursor protein and / or a nucleic acid encoding premature protein-1, cells comprising these compositions, animals comprising these compositions, methods of making these cells and animals, methods of modeling Alzheimer's disease, and methods of preparing such cells and animals. A method of assessing a treatment candidate for treating or ameliorating a symptom or phenotype of Alzheimer's disease, and a method of assessing a treatment candidate for preventing or preventing a symptom or phenotype of Alzheimer's disease.

Compounds with magnetic properties are provided herein, which belong to the category of metal oxide nanoparticles, coated and conveniently functionalized, which are conjugated with naphthalene compounds related to agglomerates and β-amyloid plaques present in neurodegenerative diseases. These new nanoparticles (NPs) are used for the non-invasive detection of agglomerates and amyloid plaques using the Magnetic Resonance Imaging (MRI) technique. The nanoparticles described here cross the blood-brain barrier (BBB), without the use of any membrane-disrupting agent. Likewise, they bind with high affinity and specificity to the agglomerates and β-amyloid plaques, and are used as contrast agents in MRI for the early detection of Alzheimer's disease (AD).

The present application relates to the use of vascular BACE1 as a therapeutic target for diseases related to cerebral small vessel injury. Specifically, it relates to the use of a substance that reduces the expression level of the beta-secretase (BACE1) gene and / or an inhibitor of the enzymatic activity of BACE1 protein in the preparation of a drug for treating or alleviating cerebrovascular disease, wherein the disease related to cerebral small vessel injury is preferably Alzheimer's disease, amyloid cerebral small vessel disease, and vascular dementia. The inventors have found that an increase in the content of BACE1 can cleave the tight junction protein Occludin, resulting in the degradation and loss of tight junction proteins between vascular endothelial cells, causing the structure and function of the blood-brain barrier to be damaged, ultimately leading to cerebral microbleeds and cognitive dysfunction and other pathological phenotypes of diseases related to cerebral small vessel injury; inhibition of the enzymatic activity of BACE1 can improve these pathological phenotypes of diseases related to cerebral small vessel injury.

The application belongs to the technical field of composite materials, and particularly discloses a fiber hybrid membrane for synchronously removing radioactive cesium and strontium as well as a preparation method and application thereof. The preparation method comprises the following steps: adjusting the pH of a beta-lactoglobulin solution, centrifuging, collecting the supernatant, filtering, dialyzing, freeze-drying, and obtaining beta-lactoglobulin monomers; dissolving the beta-lactoglobulin monomers in ultrapure water, adjusting the pH, and water-bath heating to obtain an amyloid fiber solution; adding potassium titanate to the amyloid fiber solution, adjusting the pH, and obtaining amyloid fiber loaded with titanium dioxide; and mixing the amyloid fiber loaded with titanium dioxide with activated carbon to obtain an amyloid fiber hybrid membrane. The fiber hybrid membrane for synchronously removing radioactive cesium and strontium and the preparation method and application thereof have high membrane flux, excellent adsorption selectivity and cycle performance, can accurately adsorb radioactive cesium and strontium in a complex seawater system, and do not produce secondary waste in the treatment process, and are low in price.

This invention relates to a method for preparing a plasma sample containing amyloid β-peptides for mass spectrometry analysis, comprising the following steps: a) contacting the plasma sample with a denaturing agent; b) performing a first solid-phase extraction step on the solution obtained in step a) to recover a first eluent; c) performing a second solid-phase extraction step on the first eluent obtained in step b) to recover a second eluent; and d) drying the second eluent obtained in step c) and processing it for mass spectrometry analysis, wherein the solution obtained in step d) contains intact amyloid β-peptides Aβ40 and Aβ42.